Paradice Investment Management LLC Sells 306,089 Shares of LivaNova PLC (NASDAQ:LIVN)

Paradice Investment Management LLC lowered its holdings in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 35.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 545,646 shares of the company's stock after selling 306,089 shares during the period. LivaNova makes up 3.5% of Paradice Investment Management LLC's holdings, making the stock its 13th largest position. Paradice Investment Management LLC owned approximately 1.01% of LivaNova worth $28,232,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Headlands Technologies LLC acquired a new stake in LivaNova in the third quarter worth approximately $72,000. Picton Mahoney Asset Management bought a new position in LivaNova during the third quarter valued at about $91,000. Vanguard Personalized Indexing Management LLC acquired a new position in LivaNova during the third quarter worth about $217,000. Jump Financial LLC bought a new stake in LivaNova in the third quarter worth about $273,000. Finally, Teza Capital Management LLC acquired a new stake in LivaNova in the 3rd quarter valued at about $275,000. Institutional investors own 97.64% of the company's stock.

Analyst Ratings Changes

LIVN has been the topic of a number of research reports. StockNews.com upgraded shares of LivaNova from a "hold" rating to a "buy" rating in a report on Thursday, April 25th. Mizuho raised their price objective on LivaNova from $75.00 to $80.00 and gave the stock a "buy" rating in a research note on Thursday, May 2nd. Needham & Company LLC reaffirmed a "buy" rating and set a $72.00 target price on shares of LivaNova in a research report on Wednesday, May 1st. Robert W. Baird increased their price target on LivaNova from $58.00 to $66.00 and gave the company a "neutral" rating in a research report on Thursday, May 2nd. Finally, Barclays upped their price objective on shares of LivaNova from $57.00 to $61.00 and gave the company an "equal weight" rating in a research note on Monday, February 26th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $66.20.

LivaNova Stock Down 1.5 %

Shares of LIVN stock traded down $0.92 on Friday, reaching $61.96. 309,256 shares of the company's stock traded hands, compared to its average volume of 739,017. The business's 50 day moving average price is $56.24 and its two-hundred day moving average price is $52.02. The company has a market capitalization of $3.36 billion, a P/E ratio of -103.27 and a beta of 0.92. The company has a debt-to-equity ratio of 0.50, a quick ratio of 2.71 and a current ratio of 3.17. LivaNova PLC has a 12-month low of $42.75 and a 12-month high of $64.47.

LivaNova (NASDAQ:LIVN - Get Free Report) last issued its earnings results on Wednesday, May 1st. The company reported $0.73 earnings per share for the quarter, beating analysts' consensus estimates of $0.45 by $0.28. The company had revenue of $294.90 million for the quarter, compared to the consensus estimate of $278.17 million. LivaNova had a positive return on equity of 13.59% and a negative net margin of 2.68%. The firm's quarterly revenue was up 12.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.43 EPS. On average, equities analysts forecast that LivaNova PLC will post 2.59 earnings per share for the current year.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.